Emilio Kyburz

This inventor holds 75 USPTO granted patents, primarily in Pharmaceutical Chemistry (CPC class 2602). Top assignee: Hoffmann-La Roche Inc.. Active years: 1976-1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Emilio Kyburz. Retrieved from https://idiyas.com/inventor/emilio-kyburz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 75

% Patents Active = 100.0

Average Co-Inventor Count = 2.6

ph-index = 14

Forward Citations = 798(Granted Patents)

Forward Citations (Not Self Cited) = 709(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

75 out of 5,026

Hoffmann-La Roche Inc.

patents

Years Active: 1976-1995

Loading Chart...

Areas of Expertise:

Imidazodiazepine Derivatives

Pyrrolidine Derivatives

Cognitive Diseases

Benzamide Derivatives

Hydrocinnamic Acid

Benzazecine Derivatives

Phenyl-Quinolizidines

Diazepine Derivatives

Triazolo Benzazepines

Azeto-Diazepines

Cycloheptene Derivatives

Pharmaceutical Compositions

75 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5387585 - Imidazodiazepine derivatives (1995-02-07),

2. 5238962 - Benzamide derivatives (1993-08-24),

3. 5034402 - Methods and pharmaceutical compositions using pyrrolidine derivatives (1991-07-23),

4. 5021411 - Imidazodiazepine derivatives (1991-06-04),

5. 5017608 - Hydrocinnamic acid derivatives (1991-05-21),

6. 5011849 - Compounds for treating and preventing cognitive diseases and depression (1991-04-30),

7. 4957911 - Benzazecine derivatives for cognitive and memory functions (1990-09-18),

8. 4883815 - Hydrocinnamic acid derivatives (1989-11-28),

9. 4876340 - Benzazecine derivatives for cognitive and memory functions (1989-10-24),

10. 4863920 - Imidazodiazepine derivatives for treatment of disorders of the central (1989-09-05),

11. 4775671 - Imidazodiazepines (1988-10-04),

12. 4764522 - Ethylenediamine monoamides (1988-08-16),

13. 4749791 - Benzo[f]quinoline intermediates (1988-06-07),

14. 4732979 - Benzazecine derivatives for cognitive and memory functions (1988-03-22),

15. 4691040 - Derivatives of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-ethanol (1987-09-01),

Title: Innovations and Contributions of Emilio Kyburz in Pharmaceutical Science

Introduction

Emilio Kyburz, based in Reinach, Switzerland, is a prominent inventor with an impressive portfolio of 75 patents. His groundbreaking work in the field of pharmaceuticals has led to the development of innovative compounds aimed at treating various medical conditions.

Latest Patents

Among his latest contributions are novel imidazodiazepine derivatives, which can be utilized for controlling or preventing epileptic seizures, anxiety, sleep disorders, and more. These compounds are designed to specifically target benzodiazepine receptors, which can help mitigate undesired side effects from overdosage or intensive medical use. Another significant patent includes benzamide derivatives, which have shown monoamine oxidase inhibiting properties and can be effectively used for treating depressive states and Parkinsonism.

Career Highlights

Emilio Kyburz's career has been marked by his work at Hoffmann-La Roche Inc., a leading global healthcare company. His innovative spirit and dedication to pharmaceutical research have led to the development of several life-changing therapies, positioning him as a leading figure in his field.

Collaborations

Throughout his career, Kyburz has collaborated with esteemed professionals such as Walter Hunkeler and Max Gerecke. Together, they have pushed the boundaries of pharmaceutical research, leading to advancements that benefit patients on a global scale.

Conclusion

Emilio Kyburz continues to be a vital contributor to the pharmaceutical industry with his extensive list of patents and innovative research. His work not only addresses critical medical challenges but also demonstrates the significance of innovation in enhancing human health and well-being.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]